NXTC
NextCure, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.00
−4.24%Price chart
Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$32.04M
MomentumView details →
1D Return
−4.24%
YTD Return
−48.17%
RSI (14)
56.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$32.04M
RSI (14)
56.5
MomentumView details →
1D Return
−4.24%
YTD Return
−48.17%
SummaryUpdated Jun 1, 2026
NextCure, Inc. (NASDAQ:NXTC) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Beltsville, Maryland. The company went public in May 2019 and focuses on discovering and developing novel immunotherapies to treat cancer and other immune-related diseases. NextCure's approach centers on restoring normal immune function through targeted immunomodulation, representing a specialized segment within the broader cancer immunotherapy field.
Similar companies
Latest newsMore news →
NextCure, Inc. amended its lease agreement, accelerating the lease expiration to December 31, 2027, terminating rent obligations as of September 1, 2026, and paying a lump sum of $758,648 while forfeiting a $39,292.70 security deposit.8d agoXcellon Biologics acquires a GMP manufacturing facility from NextCure, becoming an end-to-end CRDMO for next-generation bioconjugates and complex biologics.33d agoAvere, an investee of Hansoh Pharmaceutical, merges into NextCure via a merger agreement, with Hansoh expected to hold more than 30% of the combined entity's equity.60d ago